Rohde, Veit

[["dc.bibliographiccitation.firstpage","1611"],["dc.bibliographiccitation.issue","14"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","1619"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Herrlinger, Ulrich"],["dc.contributor.author","Schäfer, Niklas"],["dc.contributor.author","Weyerbrock, Astrid"],["dc.contributor.author","Hau, Peter"],["dc.contributor.author","Goldbrunner, Roland"],["dc.contributor.author","Friedrich, Franziska"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Ringel, Florian"],["dc.contributor.author","Schlegel, Uwe"],["dc.contributor.author","Sabel, Michael"],["dc.contributor.author","Ronellenfitsch, Michael W."],["dc.contributor.author","Uhl, Martin"],["dc.contributor.author","Maciaczyk, Jaroslaw"],["dc.contributor.author","Grau, Stefan"],["dc.contributor.author","Schnell, Oliver"],["dc.contributor.author","Hänel, Mathias"],["dc.contributor.author","Krex, Dietmar"],["dc.contributor.author","Vajkoczy, Peter"],["dc.contributor.author","Gerlach, Rüdiger"],["dc.contributor.author","Kortmann, Rolf-Dieter"],["dc.contributor.author","Mehdorn, Maximilian"],["dc.contributor.author","Tüttenberg, Jochen"],["dc.contributor.author","Mayer-Steinacker, Regine"],["dc.contributor.author","Fietkau, Rainer"],["dc.contributor.author","Brehmer, Stefanie"],["dc.contributor.author","Mack, Frederic"],["dc.contributor.author","Stuplich, Moritz"],["dc.contributor.author","Kebir, Sied"],["dc.contributor.author","Kohnen, Ralf"],["dc.contributor.author","Dunkl, Elmar"],["dc.contributor.author","Leutgeb, Barbara"],["dc.contributor.author","Proescholdt, Martin"],["dc.contributor.author","Pietsch, Torsten"],["dc.contributor.author","Urbach, Horst"],["dc.contributor.author","Belka, Claus"],["dc.contributor.author","Stummer, Walter"],["dc.contributor.author","Glas, Martin"],["dc.contributor.author","Steinbach, Joachim Peter"],["dc.date.accessioned","2020-12-10T18:41:29Z"],["dc.date.available","2020-12-10T18:41:29Z"],["dc.date.issued","2016"],["dc.description.abstract","Purpose In patients with newly diagnosed glioblastoma that harbors a nonmethylated O-6-methylguanine-DNA methyltransferase promotor, standard temozolomide (TMZ) has, at best, limited efficacy. The GLARIUS trial thus explored bevacizumab plus irinotecan (BEV+IRI) as an alternative to TMZ. Patients and Methods In this phase II, unblinded trial 182 patients in 22 centers were randomly assigned 2: 1 to BEV (10mg/kg every 2 weeks) during radiotherapy (RT) followed by maintenance BEV (10mg/kg every 2 weeks) plus IRI(125 mg/m(2) every 2 weeks) or to daily TMZ (75 mg/m(2)) during RT followed by six courses of TMZ (150-200 mg/m(2)/d for 5 days every 4 weeks). The primary end point was the progression-free survival rate after 6 months (PFS-6). Results In the modified intention-to-treat (ITT) population, PFS-6 was increased from 42.6% with TMZ(95% CI, 29.4% to 55.8%) to 79.3% with BEV+IRI (95% CI, 71.9% to 86.7%; P < .001). PFS was prolonged from a median of 5.99 months (95% CI, 2.7 to 7.3 months) to 9.7 months (95% CI, 8.7 to 10.8 months; P < .001). At progression, crossover BEV therapy was given to 81.8% of all patients who received any sort of second-line therapy in the TMZ arm. Overall survival (OS) was not different in the two arms: the median OS was 16.6 months (95% CI, 15.4 to 18.4 months) with BEV+IRI and was 17.5 months (95% CI, 15.1 to 20.5 months) with TMZ. The time course of quality of life (QOL) in six selected domains of the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire (QLQ)-C30 and QLQ-BN20 (which included cognitive functioning), of the Karnofsky performance score, and of the Mini Mental State Examination score was not different between the treatment arms. Conclusion BEV+IRI resulted in a superior PFS-6 rate and median PFS compared with TMZ. However, BEV+IRI did not improve OS, potentially because of the high crossover rate. BEV+IRI did not alter QOL compared with TMZ. (C) 2016 by American Society of Clinical Oncology"],["dc.identifier.doi","10.1200/JCO.2015.63.4691"],["dc.identifier.eissn","1527-7755"],["dc.identifier.isi","000375309100011"],["dc.identifier.issn","0732-183X"],["dc.identifier.pmid","26976423"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77594"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.relation.issn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","975"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Neuro-Oncology"],["dc.bibliographiccitation.lastpage","985"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Schäfer, Niklas"],["dc.contributor.author","Proescholdt, Martin"],["dc.contributor.author","Steinbach, Joachim P"],["dc.contributor.author","Weyerbrock, Astrid"],["dc.contributor.author","Hau, Peter"],["dc.contributor.author","Grauer, Oliver"],["dc.contributor.author","Goldbrunner, Roland"],["dc.contributor.author","Friedrich, Franziska"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Ringel, Florian"],["dc.contributor.author","Schlegel, Uwe"],["dc.contributor.author","Sabel, Michael"],["dc.contributor.author","Ronellenfitsch, Michael W"],["dc.contributor.author","Uhl, Martin"],["dc.contributor.author","Grau, Stefan"],["dc.contributor.author","Hänel, Mathias"],["dc.contributor.author","Schnell, Oliver"],["dc.contributor.author","Krex, Dietmar"],["dc.contributor.author","Vajkoczy, Peter"],["dc.contributor.author","Tabatabai, Ghazaleh"],["dc.contributor.author","Mack, Frederic"],["dc.contributor.author","Schaub, Christina"],["dc.contributor.author","Tzaridis, Theophilos"],["dc.contributor.author","Nießen, Michael"],["dc.contributor.author","Kebir, Sied"],["dc.contributor.author","Leutgeb, Barbara"],["dc.contributor.author","Urbach, Horst"],["dc.contributor.author","Belka, Claus"],["dc.contributor.author","Stummer, Walter"],["dc.contributor.author","Glas, Martin"],["dc.contributor.author","Herrlinger, Ulrich"],["dc.date.accessioned","2020-12-10T18:19:37Z"],["dc.date.available","2020-12-10T18:19:37Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1093/neuonc/nox204"],["dc.identifier.eissn","1523-5866"],["dc.identifier.issn","1522-8517"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75313"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","32"],["dc.contributor.author","Herrlinger, Ulrich"],["dc.contributor.author","Schaefer, Nildas"],["dc.contributor.author","Steinbach, Joachim Peter"],["dc.contributor.author","Weyerbrock, Astrid"],["dc.contributor.author","Hau, Peter"],["dc.contributor.author","Goldbrunner, Roland"],["dc.contributor.author","Friedrich, Franziska"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Ringel, Florian"],["dc.contributor.author","Braun, Christian"],["dc.contributor.author","Kohnen, Ralf"],["dc.contributor.author","Leutgeb, Barbara"],["dc.contributor.author","Belka, Claus"],["dc.contributor.author","Urbach, Horst"],["dc.contributor.author","Stummer, Walter"],["dc.contributor.author","Gies, Martin"],["dc.date.accessioned","2018-11-07T09:40:06Z"],["dc.date.available","2018-11-07T09:40:06Z"],["dc.date.issued","2014"],["dc.identifier.isi","000358613202708"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33436"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","50th Annual Meeting of the American-Society-of-Clinical-Oncology"],["dc.relation.eventlocation","Chicago, IL"],["dc.relation.issn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Survival and quality of life in the randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan versus standard temozolornide in newly diagnosed, MGMT-non-methylated glioblastoma patients"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e0234956"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","PLoS One"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Krenzlin, Harald"],["dc.contributor.author","Bettag, Christoph"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Ringel, Florian"],["dc.contributor.author","Keric, Naureen"],["dc.contributor.editor","Ashkenazi, Itamar"],["dc.date.accessioned","2021-04-14T08:25:13Z"],["dc.date.available","2021-04-14T08:25:13Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1371/journal.pone.0234956"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81555"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1932-6203"],["dc.title","Involuntary ambulatory triage during the COVID-19 pandemic – A neurosurgical perspective"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1490"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Biomedicines"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Abboud, Tammam"],["dc.contributor.author","Asendorf, Thomas"],["dc.contributor.author","Heinrich, Jutta"],["dc.contributor.author","Faust, Katharina"],["dc.contributor.author","Krieg, Sandro M."],["dc.contributor.author","Seidel, Kathleen"],["dc.contributor.author","Mielke, Dorothee"],["dc.contributor.author","Matthies, Cordola"],["dc.contributor.author","Ringel, Florian"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Szelényi, Andrea"],["dc.date.accessioned","2021-12-01T09:22:46Z"],["dc.date.available","2021-12-01T09:22:46Z"],["dc.date.issued","2021"],["dc.description.abstract","Background: Monitoring of motor function during surgery for supratentorial tumors under general anesthesia applies either transcranial electrical stimulation (TES) or direct cortical stimulation (DCS) to elicit motor-evoked potentials. To date, there is no guideline that favor one method over the other. Therefore, we designed this randomized study to compare between both methods regarding the prediction of postoperative motor deficits and extent of tumor resection. Methods: This is a multicenter (six centers in Germany and one in Switzerland), double blind, parallel group, exploratory, randomized controlled clinical trial. Patients without or with mild paresis, who are scheduled for surgical resection of motor-eloquent brain tumors under general anesthesia will be randomized to surgical resection under TES or surgical resection under DCS. The primary endpoint is sensitivity and specificity in prognosis of motor function 7 days after surgery. The main secondary endpoint is the extent of tumor resection. The study is planned to include 120 patients within 2 years. Discussion: The present exploratory study should compare TES and DCS regarding sensitivity and specificity in predicting postoperative motor deficit and extent of tumor resection to calculate the required number of patients in a confirmatory trial to test the superiority of one method over the other."],["dc.description.abstract","Background: Monitoring of motor function during surgery for supratentorial tumors under general anesthesia applies either transcranial electrical stimulation (TES) or direct cortical stimulation (DCS) to elicit motor-evoked potentials. To date, there is no guideline that favor one method over the other. Therefore, we designed this randomized study to compare between both methods regarding the prediction of postoperative motor deficits and extent of tumor resection. Methods: This is a multicenter (six centers in Germany and one in Switzerland), double blind, parallel group, exploratory, randomized controlled clinical trial. Patients without or with mild paresis, who are scheduled for surgical resection of motor-eloquent brain tumors under general anesthesia will be randomized to surgical resection under TES or surgical resection under DCS. The primary endpoint is sensitivity and specificity in prognosis of motor function 7 days after surgery. The main secondary endpoint is the extent of tumor resection. The study is planned to include 120 patients within 2 years. Discussion: The present exploratory study should compare TES and DCS regarding sensitivity and specificity in predicting postoperative motor deficit and extent of tumor resection to calculate the required number of patients in a confirmatory trial to test the superiority of one method over the other."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2021"],["dc.identifier.doi","10.3390/biomedicines9101490"],["dc.identifier.pii","biomedicines9101490"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/94481"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-478"],["dc.relation.eissn","2227-9059"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Transcranial versus Direct Cortical Stimulation for Motor-Evoked Potentials during Resection of Supratentorial Tumors under General Anesthesia (The TRANSEKT-Trial): Study Protocol for a Randomized Controlled Trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]